Skip to content

Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer

Diagnosis of Lynch Syndrome Based on the Colorectal Core™ Platform in Colorectal Cancer Patients With the Loss of Staining by Immunohistochemistry (IHC) of Any of the Mismatch Repair (MMR) Proteins: An Open-label and Multi-center Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03047226
Enrollment
311
Registered
2017-02-08
Start date
2017-02-28
Completion date
2018-07-31
Last updated
2021-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lynch Syndrome

Keywords

Lynch Syndrome, mismatch repair, microsatellite instability, next-generation sequencing, immunohistochemistry

Brief summary

The purpose of this study is to determine the proportion of patients diagnosed with Lynch syndrome in colorectal cancer patients with the loss of staining by immunohistochemistry (IHC) of any of the mismatch repair (MMR) proteins. Besides, this study aims to test the specificity and the sensitivity of detecting microsatellite instability (MSI) by next-generation sequencing, and to find out the consistency between IHC and MSI in colorectal cancer patients in China. In addition, researchers want to analyze the clinical characteristics and germline mutation of Lynch syndrome in Chinese population.

Detailed description

1. Detect microsatellite instability (by next-generation sequencing and PCR capillary electrophoresis) and germline mutation (by next-generation sequencing) in probands. 2. Analyze the test outcome with clinical and family information to evaluate the germline mutation status preliminarily: likely pathogenic germline mutation, variant of uncertain significance, non-pathogenic germline mutation. 3. Verify the germline mutation in blood relatives whose proband has known likely pathogenic germline mutation or variant of uncertain significance. 4. Diagnose pathogenic germline mutation and non-pathogenic germline mutation based on clinical characteristics, family information and germline mutation test outcomes (including the outcomes of probands and blood relatives). Diagnose Lynch syndrome and the pathogenic germline mutation carriers in the included population. 5. Analyze the specificity and the sensitivity of detecting microsatellite instability (MSI) by next-generation sequencing; and analyze the consistency between IHC and MSI. 6. Analyze the clinical characteristics and germline mutation of Lynch syndrome in Chinese population.

Interventions

Use next-generation sequencing to test germline mutation and microsatellite instability.

Sponsors

Guangzhou Burning Rock Medical Examination Institute Co., Ltd.
CollaboratorINDUSTRY
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

For probands, the inclusion criteria: All of the following four points should be satisfied: * Histological diagnosis of colorectal cancer; * With the loss of staining by immunohistochemistry of any of the mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, PMS2); * With sufficient tumor tissue and normal tissue to test; * Agree to provide basic information, clinical information and family history of cancer information. For probands, the

Exclusion criteria

* With at least one blood relative with known pathogenic germline mutation(s). For blood relatives verifying germline mutation, the inclusion criteria: All of the following three points should be satisfied: * First- to second-degree blood relatives of probands with germline mutation(s). * With Sufficient tumor tissue and normal tissue to test. * Agree to provide basic information, clinical information and family history of cancer information. For blood relatives verifying germline mutation, the

Design outcomes

Primary

MeasureTime frameDescription
Pathogenic germline mutationUpon completion of study, on average 2 years.Pathogenic germline mutation using next-generation sequencing with a targeted panel.

Secondary

MeasureTime frameDescription
Variant of uncertain significance of germline mutationUpon completion of study, on average 2 years.Variant of uncertain significance of germline mutation using next-generation sequencing with a targeted panel.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026